Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

JAMA Oncology Author Interviews
15/04/2021 15 min
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

Listen "Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC"

Descargar episodio Ver en sitio original

Episode Synopsis

Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

More episodes of the podcast JAMA Oncology Author Interviews

Metastatic Recurrence Among Adolescents and Young Adults With Cancer 26/11/2025
Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality 30/10/2025
Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer 18/09/2025
Proportional Sedation for Persistent Agitated Delirium in Palliative Care 31/07/2025
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance 29/05/2025
Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury 24/04/2025
Accelerated Aging in Survivors of Childhood Cancer 20/03/2025
Academic-Community Partnership and Deaths in Promyelocytic Leukemia 27/02/2025
Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy 30/01/2025
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 05/12/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA